Its turnover grew 40% on the year in the first quarter, to RON149 million.

Its operating profit stood at RON38.45 million in the first quarter, mainly due to the change of business model which took place following the separation from Sanofi.

Profit was positively influenced by the increased turnover, which is mainly due to the fact that starting from September 2018, Zentiva SA sells goods destined for the local market directly to wholesalers, the company said.

In 2018, after nine years, France’s Sanofi discarded its generics division and sold Zentiva to Advent International. Zentiva group has production facilities in Bucharest and Prague.

Zentiva Romania had consolidated sales of RON461 million in 2018 and a profit of RON262 million, nearly triple compared with 2017, following separation from Sanofi.